Jane Street Group LLC purchased a new stake in Acceleron Pharma Inc. (NASDAQ:XLRN) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 39,137 shares of the biopharmaceutical company’s stock, valued at approximately $1,461,000. Jane Street Group LLC owned about 0.09% of Acceleron Pharma as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in shares of Acceleron Pharma by 9.0% in the second quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock valued at $121,719,000 after buying an additional 330,635 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Acceleron Pharma by 6.1% in the second quarter. Vanguard Group Inc. now owns 2,029,040 shares of the biopharmaceutical company’s stock valued at $61,663,000 after buying an additional 116,705 shares during the last quarter. Westfield Capital Management Co. LP raised its holdings in shares of Acceleron Pharma by 46.6% in the second quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock valued at $51,127,000 after buying an additional 534,440 shares during the last quarter. Eagle Asset Management Inc. raised its holdings in shares of Acceleron Pharma by 6.6% in the second quarter. Eagle Asset Management Inc. now owns 1,256,642 shares of the biopharmaceutical company’s stock valued at $38,189,000 after buying an additional 77,683 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Acceleron Pharma by 9.4% in the second quarter. State Street Corp now owns 1,131,824 shares of the biopharmaceutical company’s stock valued at $34,386,000 after buying an additional 97,199 shares during the last quarter. 85.84% of the stock is owned by institutional investors and hedge funds.

Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) opened at $35.68 on Monday. Acceleron Pharma Inc. has a twelve month low of $23.07 and a twelve month high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.02. The company had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. Acceleron Pharma’s revenue was up .0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.55) EPS. sell-side analysts predict that Acceleron Pharma Inc. will post -2.65 EPS for the current year.

A number of research firms recently issued reports on XLRN. Royal Bank Of Canada began coverage on Acceleron Pharma in a report on Thursday, September 14th. They issued a “sector perform” rating and a $44.00 price target for the company. Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a report on Wednesday, September 20th. Cann reissued a “hold” rating on shares of Acceleron Pharma in a report on Tuesday, September 5th. UBS reissued a “buy” rating and set a $50.00 price objective (up from $36.00) on shares of Acceleron Pharma in a report on Tuesday, September 12th. Finally, ValuEngine cut Acceleron Pharma from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $44.56.

In related news, major shareholder Corp /De/ Celgene purchased 745,592 shares of the stock in a transaction dated Monday, September 25th. The stock was bought at an average cost of $37.00 per share, with a total value of $27,586,904.00. Following the purchase, the insider now directly owns 6,118,479 shares in the company, valued at approximately $226,383,723. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Christopher Rovaldi sold 14,000 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $38.41, for a total value of $537,740.00. Following the completion of the sale, the senior vice president now directly owns 28,232 shares of the company’s stock, valued at $1,084,391.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 53,513 shares of company stock valued at $2,055,485. 3.90% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/11/jane-street-group-llc-purchases-new-holdings-in-acceleron-pharma-inc-xlrn.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc. (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Stock Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related stocks with our FREE daily email newsletter.